Dividend Information About AbbVie: Everything You Need to Know Before Its Ex-Dividend Date on Oct 15, 2025
Generated by AI AgentAinvest Dividend Digest
Saturday, Oct 11, 2025 7:24 pm ET1min read
ABBV--
Aime Summary
AbbVie (ABBV) has announced its upcoming cash dividend, offering shareholders $1.64000 per share. The dividend will be paid out on Nov 14, 2025, with an ex-dividend date set for Oct 15, 2025. Shareholders must own the stock by the close of trading on Oct 15, 2025, to be eligible for this payout. The company made the announcement on Sep 5, 2025, marking the formal declaration of the upcoming dividend. The most recent dividend was also $1.64000 per share, paid on Aug 15, 2025, and was also a cash dividend. The average of the last 10 dividend amounts stands at $0.99196 per share, meaning this time’s payout is significantly higher compared to the historical average. These details highlight AbbVie’s consistent dividend policy and its current generous payout to shareholders.
Over the past week, AbbVieABBV-- has attracted attention due to several key developments. Most recently, the company announced its intention to host a third-quarter 2025 earnings conference call, signaling its readiness to provide updated financial insights to the market. Analysts have noted a positive shift in sentiment, with price targets raised to $232.78, reflecting expectations of strong growth from recent strategic initiatives. As of late, AbbVie’s stock has demonstrated solid performance, with a 30-day share price return of nearly 10% and a year-to-date gain exceeding 28%, building momentum and reinforcing investor confidence. Additionally, the stock has been rated “Buy” by key market participants, with a 12-month target price of $232.85, indicating a slight upside from the current price of $230.50. These developments collectively point to a strengthening business outlook and favorable market conditions for AbbVie.
With these positive fundamentals and a generous dividend offering, AbbVie continues to attract both income-focused and growth-oriented investors. The ex-dividend date of Oct 15, 2025, marks the final opportunity for investors to purchase shares and receive the $1.64000 per share dividend. Investors who buy the stock after this date will not be eligible for the upcoming payout, underscoring the importance of timing for those seeking to benefit from AbbVie’s current dividend yield.
Over the past week, AbbVieABBV-- has attracted attention due to several key developments. Most recently, the company announced its intention to host a third-quarter 2025 earnings conference call, signaling its readiness to provide updated financial insights to the market. Analysts have noted a positive shift in sentiment, with price targets raised to $232.78, reflecting expectations of strong growth from recent strategic initiatives. As of late, AbbVie’s stock has demonstrated solid performance, with a 30-day share price return of nearly 10% and a year-to-date gain exceeding 28%, building momentum and reinforcing investor confidence. Additionally, the stock has been rated “Buy” by key market participants, with a 12-month target price of $232.85, indicating a slight upside from the current price of $230.50. These developments collectively point to a strengthening business outlook and favorable market conditions for AbbVie.
With these positive fundamentals and a generous dividend offering, AbbVie continues to attract both income-focused and growth-oriented investors. The ex-dividend date of Oct 15, 2025, marks the final opportunity for investors to purchase shares and receive the $1.64000 per share dividend. Investors who buy the stock after this date will not be eligible for the upcoming payout, underscoring the importance of timing for those seeking to benefit from AbbVie’s current dividend yield.

Sip from the stream of US stock dividends. Your income play.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet